How long will marijuana show in a drug test?

Why THC is the longest-detected analyte in routine panels

Delta-9 tetrahydrocannabinol (THC) is the principal psychoactive cannabinoid in cannabis. After exposure, the liver rapidly converts it to 11-hydroxy-THC and then to the inactive carboxylic-acid metabolite 11-nor-9-carboxy-THC, commonly written THC-COOH. Urinary immunoassays for marijuana target THC-COOH — not the parent THC — because the metabolite is excreted in much higher concentrations and remains detectable far longer.

THC and THC-COOH are profoundly lipophilic. They partition into adipose tissue with each exposure and slowly redistribute back into circulation over days to weeks as fat stores turn over. The result is a detection profile unlike any other commonly tested substance: a long, slow elimination tail in chronic users that can extend a urinary positive far beyond the donor's last use. This is not a quirk of the assay — it is a pharmacokinetic property of the molecule.

Because THC sits in fat and not in plasma water, conventional half-life math does not predict urinary detection. Published terminal half-life estimates range from 1.3 days for an occasional user to 5–13 days in chronic users, with whole-body elimination measured in weeks. Programs that treat THC like other substances — applying a generic "3–5 days" rule — routinely misjudge their own positivity windows.

Detection windows by matrix

The same donor will produce very different results across specimen matrices. Each matrix answers a different question — recent use, cumulative exposure, or long-window lookback — and program design should match matrix to question.

Specimen-matrix collection logistics and limitations

Each matrix introduces collection requirements that program administrators should understand before selecting a panel format. Urine collection in regulated settings follows the SAMHSA Mandatory Guidelines protocol — donor identification, a secured collection area with no water source, bluing agent in the toilet bowl, taped faucets, temperature-strip reading within four minutes of void (90–100°F), and chain-of-custody documentation on the Federal Custody and Control Form. Unobserved urine collection is the workplace default and is operationally compatible with CLIA-waived point-of-care immunoassay devices. Observed collection is reserved for return-to-duty, follow-up after a prior violation, a previously dilute or invalid specimen, or contemporaneous donor-behavior triggers documented by the collector.

Oral-fluid collection is inherently observed because the collector watches the donor place the absorbent collection pad into the mouth. This removes a category of donor-substitution and adulteration concerns that urine collection cannot fully eliminate. SAMHSA oral-fluid guidance specifies a pre-collection observation period (typically ten minutes with no oral intake) to limit acute external contamination from food, beverages, or recent smoke exposure. For THC specifically, oral fluid is well suited to post-accident and reasonable-suspicion testing because the parent-drug window of roughly 24–72 hours correlates more closely with recent exposure than a urinary THC-COOH window measured in weeks for chronic users.

Hair testing extends the lookback but introduces matrix-specific limitations that should be documented in any program policy that relies on it. The standard 1.5-inch scalp sample represents roughly 90 days of growth at the population-average rate of 0.5 inch per month — individual growth rates vary, and hair growing on different body regions grows at different rates and reflects different time windows. Hair color bias has been documented in the toxicology literature: melanin in darker hair binds basic drugs (cocaine, methamphetamine, opioids) more avidly than lighter hair, which can produce higher analyte concentrations at the same dose. THC is less affected because the molecule is not strongly basic, but the bias remains a recognized limitation of hair testing as an across-population comparator and is one of the reasons hair is not currently a SAMHSA-authorized matrix for federal workplace programs.

External-contamination control in hair testing relies on a mandatory pre-analytical wash protocol and on simultaneous measurement of parent THC alongside the THC-COOH metabolite. THC-COOH is formed only by hepatic metabolism — it cannot be deposited from environmental smoke — while parent THC can adhere to the keratin matrix from passive smoke exposure. The ratio of metabolite to parent compound is the principal discriminator between active use and external contamination. Body hair (chest, axillary, leg) reflects a longer, less time-resolved exposure window than scalp hair and is generally accepted only when scalp hair is unavailable in sufficient length.

The individual factors that move the window

No two donors produce the same elimination curve, even at the same exposure level. The pharmacokinetics of THC interact with body composition, hepatic function, hydration, and the specific cannabis product consumed to widen the published ranges substantially.

Frequency of use is the dominant variable. A single low-dose exposure clears urine within a week. Daily use produces a tissue reservoir that releases THC-COOH for weeks after the last exposure. Studies of cannabis-treatment populations have documented urinary positivity at 20 ng/mL for 46 days on average in daily users, with some individuals positive past 77 days. Frequency, not potency alone, drives the long tail.

Dose and product potency matter independently of frequency. Modern flower commonly tests at 18–25% THC; concentrates and vape products can exceed 70%. Edibles produce a larger 11-hydroxy-THC peak because of first-pass hepatic metabolism, and the prolonged absorption from gastrointestinal exposure extends the elimination tail. Higher per-occasion exposure deposits more THC into adipose tissue, and the resulting tissue reservoir takes proportionally longer to clear.

Body composition affects the size of the reservoir. Adipose tissue stores lipophilic compounds, so higher body-fat percentage extends THC detection — particularly in donors who use chronically. Conversely, rapid weight loss after sustained use can transiently elevate urinary THC-COOH as fat stores mobilize and release stored cannabinoids back into circulation. This is a real, documented effect, not a folk theory.

Hepatic and renal function determine clearance of the metabolite. CYP-pathway-inducing medications (rifampin, carbamazepine, certain antiretrovirals) generally shorten the window; CYP inhibitors generally extend it. Hydration affects urinary concentration in a given sample without altering total body burden — federal programs use creatinine and specific-gravity checks to identify dilute specimens.

Second-hand smoke and passive exposure

Passive exposure to cannabis smoke has been studied extensively because of repeated donor claims and the legitimate possibility of incidental exposure in social and household settings. The consensus from controlled chamber studies is that passive exposure under realistic ventilation conditions rarely produces a urine positive at the SAMHSA 50 ng/mL immunoassay cutoff or at the 15 ng/mL GC/MS confirmation cutoff. The federal cutoffs were chosen specifically to make passive-exposure positives implausible.

Under extreme, unventilated, multi-hour exposure to high-potency smoke — the so-called "Cottam chamber" or "hotbox" conditions — passive exposure can produce transient urinary THC-COOH detectable at the 20 ng/mL clinical cutoff. These conditions are unusual outside of research protocols. Real-world environmental exposure at concerts, restaurant patios, or open-air gatherings does not produce SAMHSA-cutoff positives in controlled studies.

Oral fluid is more susceptible to acute environmental contamination because passive smoke can deposit parent THC directly onto the oral mucosa. SAMHSA oral-fluid guidelines incorporate a confirmation cutoff designed to distinguish active use from incidental exposure, and donors are typically required to wait a brief period after potential exposure before collection. Hair testing has its own external-contamination considerations, addressed by mandatory washing protocols and by simultaneous measurement of THC-COOH (formed only internally) alongside parent THC (which can deposit externally).

CBD products, hemp contamination, and unexpected positives

The 2018 Farm Bill federally legalized hemp-derived cannabinoids containing no more than 0.3% delta-9 THC by dry weight. That threshold is a regulatory definition, not a guarantee that a finished CBD product contains no measurable THC. Independent testing has repeatedly found mislabeled CBD products containing THC above the legal threshold — sometimes substantially above. Donors using high-volume daily CBD oil can accumulate enough THC exposure to produce a positive urine result, even when label claims indicate THC-free.

Hemp-derived isomers add a further complication. Delta-8 THC, delta-10 THC, HHC (hexahydrocannabinol), and THC-O acetate are widely marketed in states without regulated cannabis programs. These compounds and their metabolites cross-react with marijuana immunoassays, and confirmation by GC/MS or LC-MS/MS distinguishes the specific cannabinoid present but does not necessarily exonerate the donor under most workplace policies that prohibit THC isomers categorically. Programs operating in states with widespread hemp-isomer retail should expect MRO discussions about delta-8 exposure.

Synthetic cannabinoids — the K2/Spice class — do not cross-react with marijuana immunoassays at all. They are detected only on a specific synthetic-cannabinoid panel. A program concerned about K2/Spice use cannot rely on its marijuana screen to detect it; a dedicated panel is required.

Cutoffs, confirmation, and specimen-validity workflow

Regulated THC testing uses a two-step workflow: an immunoassay screen at the SAMHSA 50 ng/mL cutoff for THC-COOH, followed by GC/MS or LC-MS/MS confirmation at 15 ng/mL on any presumptive positive. DOT testing under 49 CFR Part 40 applies the same cutoffs. The screen-to-confirmation gap is intentional — the higher screening cutoff limits false presumptive positives at point of collection, while the lower confirmation cutoff verifies the specific analyte and produces a defensible quantitative value for the MRO record. A presumptive-positive screen with a sub-15 ng/mL confirmation is reported as negative; a sub-50 ng/mL screen is not reflexed to confirmation at all under the federal protocol.

Non-regulated CLIA-waived workplace programs commonly mirror SAMHSA at 50/15 to keep their programs defensible against challenge. Clinical and treatment programs frequently move down to a 20 ng/mL screen, with 15 ng/mL confirmation, for chronic-use monitoring — accepting the trade-off of more presumptive positives during the long elimination tail in patients who have actually stopped using. Some abstinence-monitoring programs adopt 5 ng/mL or 10 ng/mL confirmation cutoffs in serial-testing protocols where the analytical question is trend rather than threshold. Programs that adjust cutoffs should document the rationale in the written testing policy and ensure that the MRO and laboratory partners are explicitly aligned on the chosen thresholds.

Specimen-validity testing accompanies every regulated urine collection and should accompany every defensible non-regulated collection. The standard validity panel measures creatinine (a dilution indicator — federal protocols flag specimens as dilute below 20 mg/dL and as substituted below 2 mg/dL), specific gravity (cross-checked against creatinine, with parallel federal cutoffs), urinary pH (in-range 4.5–9.0; out-of-range pH below 4.0 or above 11.0 indicates adulteration), and oxidants/nitrites that flag common adulterant chemicals. Specimens flagged as dilute, substituted, adulterated, or invalid are reported separately and trigger MRO review and, frequently, a recollection under direct observation per 49 CFR Part 40 Subpart F procedures.

The MRO review process for a confirmed THC positive in a regulated program follows the SAMHSA workflow: the laboratory reports the quantitative THC-COOH confirmation to the MRO; the MRO contacts the donor and offers an opportunity to discuss legitimate medical explanations; the MRO evaluates any documentation provided; and the MRO either verifies the result as positive or reports it to the employer as negative with documentation. Federal MRO guidance does not accept CBD use, hemp-derived isomer exposure, or recreational use in a state with legal cannabis as legitimate medical explanations for a verified THC positive in a SAMHSA- or DOT-covered program. Non-regulated employers retain discretion but typically adopt the same standard for consistency.

Program design implications

Federally regulated workplace programs — DOT-covered transportation employees and federal civilian programs under SAMHSA Mandatory Guidelines — are bound to the 50 ng/mL screen and 15 ng/mL confirmation cutoffs and have no flexibility to adjust them. Non-federal employers commonly adopt these same cutoffs by reference. Programs that deviate downward to 20 ng/mL for clinical or treatment monitoring will detect more long-tail use and produce more legitimate-positive findings in chronic users — at the cost of more donor disputes about timing of last use.

Treatment programs monitoring abstinence from cannabis face a unique challenge: a patient who genuinely stops using on day one of treatment can continue to produce positive urines for weeks, simply because of tissue release. Clinical guidance is to track THC-COOH-to-creatinine ratios over time rather than treat each positive as evidence of new use; a falling ratio is consistent with cessation. Programs that adverse-act on each individual positive without considering the trajectory often penalize patients who have, in fact, stopped using.

Pre-employment and reasonable-suspicion programs in states with cannabis-employment-protection statutes must consult counsel before testing for THC. Jurisdictions including New York, New Jersey, California, Connecticut, Nevada, and Washington now restrict pre-employment THC testing, prohibit adverse action based solely on a positive THC result, or extend protections to registered medical-marijuana patients. Federal employers, federal contractors, and DOT-regulated employees remain subject to federal rules regardless of state law.

For employers concerned with current impairment rather than weekend use, oral fluid is the better matrix. Its shorter detection window correlates more closely with recent exposure, and SAMHSA has authorized oral fluid as a federal matrix with dedicated mandatory guidelines. Programs operating in cannabis-legal states are increasingly migrating reasonable-suspicion and post-accident testing to oral fluid for exactly this reason.